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side evaluation as potential predictors of death in the 7,796 subjects enrolled in the 
GUSTO IV tdal with 301 deaths at 30 days (3.86%). Univariate logistic regression models 
were fit to the data and then multivariate logistic regression models were developed and 
creating a simplified scoring system using the Hosmer-Lemeshow goodness of fit statis- 
tics and c-index. The predictive accuracy of the multivadable model was assessed using 
bootstrap methods. 
Results: The final multivariate model included age (2 points plus additional 2 points for 
every decade above 50), 4 major criteria (history of heart failure, stroke/transient 
ischemic attacks, renal insufficiency or elevated CK-MB - each 2 points) and 6 minor pre- 
dictors (elevated troponin and C-reactive protein, ST depression, anemia, hypercholes- 
terolemia and history of coronary disease - each 1 point). Thirty-day mortality increased 
significantly with a dsing score (0.29% for 0-4 points, 1.75 % for 5-9 points; 7.17% for 11- 
14 points, 24% for >15 points). This model provides a robust risk scoring system with a c- 
index of 0.797 (range from 0.744 to 0.841 using bootstrap methods, compared to 0.56 in 
the TIMI risk score for 14-day mortality). In the final multivariate model, traditional risk 
factors such as male gender, diabetes mellitus, hypertension, prior aspidn use, recent 
angina and current smoking history has little effect on the model performance in predict- 
ing 30-day mortality. 
Conclusion: The GUSTO risk score provides a simple and easy-to-use risk scoring sys- 
tem that incorporates multiple factors in predicting 30-day risk of death in patients pre- 
senting with ACS. This risk score illustrates the importance of age and comorbid 
conditions in the process of risk stratification. 
10:15 a.m. 
801-5 One-Year  Fo l low-Up o f  Morta l i ty  in the GUSTO IV Trial 
Evaluating the Effects of 24 - 48 Hours Abciximab 
Infusion in Noninvaeively Managed Acute Coronary 
Syndrome Patients 
Msarten Simoons. Paul Armstrong, Elliot Barnathane, Robert Califf, Stefan James, Eric 
Topoi, Lars Wallentin, the GUSTO-IV ACS trialists, Department of cardiology, Rotterdam, 
The Netherlands, Thoraxcanter, Uppsala, Sweden. 
Background: The long-term efficacy of abciximab (Abx) treatment is proven in acute cor- 
onary syndrome (ACS) patients undergoing eady revascularisation. However, as medical 
treatment in primarily noninvasively managed patients, Abx did not provide any advan- 
tages compared to placebo in the GUSTO IV trial. We now present the 1-year follow-up. 
Methods: The multinational prospective doubts-blind trial of the efficacy of abciximab as 
the pdmary medical treatment in ACS without early revasculadzation. The trial included 
7800 patients with chest pain within 24 hours and either ST-segment depression or ele- 
vation of treponin at entry. The patients were randomized to bolus injection followed by 
24 hours (n=2590) or 48 hour (n=2612) infusion of Abx or corresponding placebo 
(n=2598) in addition to heparin and aspidn. At 30 days follow up there were no differ- 
ences between the groups regarding deaths and/or myocardial infarctions. Information 
on mortality was collected after 1 year. Pre-specified subgroups were (amongst others) 
gender and body-weight. 
Results: Mortality at one year: 
*No statistical differences between groups 
Conclusion: At one year there was no difference in mortality between the randomized 
treatment groups. However in the abciximab 46 hours group there was a trend for a 
higher mortality compared to placebo. In the subgroup with body weight below 75 kg 
there was a significant increased mortality. This might indicate possible dose-related 
harmful effects of abciximab at long-term infusion. 
Mortality at one year 
Placebo Abx 24 h Abx 48 h Abx 24+48 h 
Total mortality 7.8% (203) 8.2% (212) 9.0% (234) 8.6% (446) 
p-values vs placebo 0.62 0.14 0.25 
Males* 7.7% (124) 7.4% (118) 8.6% (143) 8.0% (261) 
Females* 8.0% (79) 9.4% (84) 9.6% (91) 9.5% (185) 
<75 kg 8.6% (107) 8.9% 115) 11.4% (142) 10.1% (257) 
p-values vs placebo ns 0.02 0.13 
>75 kg 7.t% (57) 8.1% (65) 7.0% (61) 7.5% (126) 
p-values vs placebo ns ns ns 
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804-1 Cl in ica l  Benefits of Glucose-Insulin-Potassium Infusion 
in Coronary  Ar tery  Bypass Grafting: Is Improved 
Diastolic Function the Mechanism? 
Michael W. Tsaqg, Ravin Davidoff, J. Frederick Hesselvik, Hao Nguyen, Oz M. Shapira, 
Boston Medics~ Center, Boston, Massachusetts. 
Background: Glucose-Insulin-Potassium (GIK) infusion improves clinical outcome post 
CABG. The mechanism of benefit is unclear, but GIK limits ischemia and reperfusion 
injury. This study was designed to assess whether the benefit of GIK is mediated through 
a reduction in the degree of diastolic dysfunction that occurs post CABG. 
Methods: 31 patients undergoing CABG were randomized to GIK vs no GIK. LV compli- 
ance, using pressure-area relationships, was assessed by simultaneous TEE measure- 
ment of LV end-diastolic area (LVEDA) and pulmonary capillary wedge pressure (PCWP) 
at baseline, post cardiopulmonary bypass (CPB), and serially up to 3 hours post-op. 
LVEDA was measured at a constant PCWP, thus a decrease in LVEDA reflects a leftward 
shift in the pressure-area relationship consistent with decreased compliance. 
Results: Both groups demonstrated universal and progressive worsening of LV compli- 
ance. Transmittal E wave deceleration time decreased consistent with restrictive LV fill- 
ing. GIK did not alter either measure of diastolic function significantly. 
Conclusion: Diastolic dysfunction occurs nearly universally after CPB, worsens with 
chest closure, persists for up to 3 hours into the postoperative period, and is unaffected 
by GIK. This confirms that diastolic dysfunction post CABG is a result of both myocardial 
and mechanical factors. Despite theoretical reasons why GIK might limit ischemic injury, 
clinical benefits do not appear to be related to amelioration of diastolic dysfunction. 
*No statistically significant difference between the 2 groups 
LVEDA (om 2) Baseline Off CPB Chest Closed 3 Hour =)-value (trend~ 
NoGIK 17.5+4.6 15.7_+4.2 15.0_+3.2 14.3_+3.5 <0.001 
GIK * 16.3+2.8 14.9_+2.8 14.2_+2.4 13.8_+2.9 <0.001 
E Decel (sec) 
No GIK 0.21+.05 0.20_+.04 0.18_+.03 0.17_+.04 0.002 
GIK * 0.23+.04 0.21-+.04 0.20-+.04 0.18_+.05 0.0017 
9:30 a.m. 
804-2 Is V i tamin  C Super io r  to  Di l t iazem for  Radia l  Ar tery  
Vasodilation in Patients Awaiting Coronary Artery 
Bypass Grafting? A Randomized Double Blind Study 
George E. Drossos, Ioannis K. Toumpoulis, Demosthenes G. Katdtsis, John P. Ioannidis, 
Persephone Kontogiorgi, Eugenia Svama, Stavros Siminelakis, Constantine I~, 
Anaanostoooulo~, University of Ioannina School of Medicine, Ioannina, Greece, St 
Luke's~Roosevelt Hospita/ Center at Co/umbia Univerei~ New York, New York. 
Background The perioperative use of a vasodilator appears to be important in assuring 
the success of radial artery conduits. Vitamin C (vit C) has been shown to reverse endot- 
helial dysfunction in smokers and patients with coronary artery disease (CAD) or other 
predisposing factors. It is not known whether vitamin C could be used instead of calcium 
channel blockers as a vasodilator in coronary patients receiving radial artery conduits. 
Methods In a case-control study (study I), oral single-dose vit C (2g) was given to 15 
healthy non-smokers and 15 matched healthy smokers. In a randomized, double blind 
study (study II), oral single-dose vit C (2g) (n=15) and diltiazem (180mg) (n=15) were 
compared in preoperative patients with CAD. We examined the flow-mediated dilation 
with high-resolution ultrasound and color Doppler images and measurement of the lumen 
surface of the non-dominant radial artery just before and two hours after drug administra- 
tion. 
Results In study I, both smokers and non-smokers showed a significant increase in 
lumen surface at 2 hours compared with baseline (p<0.001 and p=0.013, respectively). 
This was larger in smokers (median 37.5% vs. 14.3%, p=0.004). In study II, both groups 
showed significant increases in lumen surface at 2 hours compared with baseline values 
(p<O.001 and p=0.008 for vit C and diltiazem, respectively). Vit C achieved a larger 
increase than diltiazem (median 33.3% vs. 18.2%, p=0.016), in multivariate modeling, 
the increase in lumen surface was independently predicted by use of vit C over diltiazem 
(+21.2%, p=0.007), diabetes menitus (+14.5%, p=0.085), elevated cholesterol (+26.2%, 
p=0.001) and smoking history (+20.8%, p=0.017). 
Conclusions Vit C is a potent acute vasodilator in both smokers and non-smokers. In 
patients awaiting coronary artery bypass grafting, an oral dose of vitamin C results in 
greater vasodilation of the radial artery within 2 hours, as compared with an oral dose ot 
diltiazem. 
